GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax ... years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Teva Pharmaceutical Industries Ltd. ADR-0.62% $20.28B ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE ... including one CR and 7 PRs. 3 ...

Blenrep trial shows 42% lower mortality risk; peak-year sales expected over £3 billion. Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK ...

After hours: February 3 at 6:25:46 p.m. EST ...

The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...